A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
← catalyst calendarNCT06330064 · readout in 706 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
680estimated
Sites
120
Countries
Argentina, Australia, Belgium +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-10 | actual | When the study began enrolling |
| Primary completion | 2028-07-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-25 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Recurrent or Metastatic Solid Tumors
Intervention
- Drug: Ifinatamab deruxtecan — also filed as I-DXd
Primary outcomes
what the primary-completion date above is the date OFObjective Response Rate (ORR) as Assessed by Investigator
measured From the time of the first dose of study drug until the date of documented disease progression, death, loss to follow-up, or withdrawal by the subject, whichever occurs first (up to approximately 60 months)
Number of Participants Reporting Dose-limiting Toxicities (DLTs) in the HCC Cohort
measured Cycle 1 Day 1 to Cycle 1 Day 21
Number of Participants Reporting TEAEs and Death in the HCC Cohort
measured From date of signing the informed consent form up to 47 days after the last dose of study drug, up to approximately 60 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed